An observational study in Type2 Diabetes Mellitus and Coronary Heart Disease, sponsored by Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA. Completed at 12 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.
Sponsored by Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Coronary Disease with a site in Portugal — 2 open to participants now, 3 under way, none of them phase 3. Coronary Disease · Portugal.
Among the 13 studies in Coronary Disease with a site in Portugal, this one is one of 2 that started in 2021, is one of 3 observational ones, and was the 12th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →2 of the 13 studies in Coronary Disease with a site in Portugal are open now. Recruiting first, the newest first:
University of Lisbon · Sites in Portugal
Ages 18+
Tampere University · Sites in Portugal, Finland, Germany and 3 more countries
Ages 30–80
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2 · Phase 4 1
First in 2002; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,000 is close to the median of 916 across 478 observational studies indexed under Coronary Disease.
Median enrollment 1,979 across the 10 interventional studies, 1,000 across the 3 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 13 have an industry lead sponsor. The 10 most frequent:
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA has 1 study filed under Coronary Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Coronary Disease with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04433052Tampere UniversityClinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD | 2026-12 |
| NCT07910812University of LisbonImpact of a Tailored Digital Intervention on Sedentary Behaviour and Physical Health in Long-term Cardiac Rehabilitation Patients | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies in Coronary Disease with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetes mellitus (DM) is one of the main risk factors for ischemic events in patients with coronary artery disease (CAD) and diabetes is a factor in several post-PCI (Percutaneous Coronary Intervention) risk scores. However, until recently, there were almost no studies performed specifically in the diabetic population of patients undergoing PCI. This study aims to describe the anti-thrombotic regimens, clinical outcomes and current diabetes medical treatment in an unselected consecutive population of patients with DM undergoing PCI.
Diabetes is one of the main risk factors for ischemic events in patients with coronary artery disease and diabetes is a factor in several post-PCI risk scores (including the commonly used DAPT score). However, until recently, there were almost no studies performed specifically in the diabetic population of patients undergoing PCI. At large, results from randomized trials assessing the duration of DAPT have produced conflicting results and there is uncertainty about the best anti-thrombotic strategy in patients with diabetes. Further assessment of the patterns of use and their clinical effects, including those related to prolonged DAPT is needed, in diabetic patients, especially in less selected "real world" populations.
1000 Type 2 Diabetes mellitus consecutive patients submitted to PCI in 12 interventional Cardiology Portuguese centers
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with type 2 Diabetes mellitus (previously diagnosed or diagnosed at index admission) submitted to PCI
Other: Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
Exposure to Anti-thrombotic treatment agents and glucose lowering therapy
Enumeration of the anti-thrombotic agents prescribed to patients
Time frame: Baseline to 24 months follow-up
Planned duration of dual anti-platelet treatment (DAPT) after the PCI.
Time frame: From index admission to 24 months follow-up
Adherence to anti-thrombotic regimen
Classified qualitatively according to the assessment of the attending physician.
Time frame: 6 to 24 months follow-up
Actual duration of DAPT (if different from the planned duration)
Time frame: 6 to 24 months follow-up
Reasons for interrupting DAPT at a time different from the planned duration
Time frame: 6 to 24 months follow-up
Reasons for prolonging DAPT over 1 year
Time frame: 12 to 24 months follow-up
Major Adverse Coronary Events (MACE)
Major Adverse Coronary Events (MACE) (death from any cause, new spontaneous acute myocardial infarction, stroke).
Time frame: 6 to 24 months follow-up
Death rate from any cause
Time frame: 6 to 24 months follow-up
Rate of cardiovascular death
Time frame: 6 to 24 months follow-up
Rate of new spontaneous acute myocardial infarction
Time frame: 6 to 24 months follow-up
Rate of hospital admissions for acute coronary infarction
Time frame: 6 to 24 months follow-up
Rate of unplanned coronary revascularization
Time frame: 6 to 24 months follow-up
Rate of stroke/transient ischemic attack
Time frame: 6 to 24 months follow-up
Death rate from heart failure
Time frame: 6 to 24 months follow-up
Rate of hospital admission due to heart failure
Time frame: 6 to 24 months follow-up
Rate of bleeding events of type 3-5 of BARC (Bleeding Academic Research Consortium) scale
The BARC (Bleeding Academic Research Consortium) scale will be used. The minimum and maximum scores of the scale are, respectively, type 0 (no bleeding) and type 5 (fatal). There will only be collected the events corresponding to type 3-5 of BARC scale.
Time frame: 6 to 24 months follow-up
Rate of bleeding events of type 1-5 of BARC (Bleeding Academic Research Consortium) scale
The BARC (Bleeding Academic Research Consortium) scale will be used. The minimum and maximum scores of the scale are, respectively, type 0 (no bleeding) and type 5 (fatal). There will be collected the events corresponding to type 1-5 of BARC scale.
Time frame: 6 to 24 months follow-up
Percentage of patients treated with different glucose-lowering drugs.
Time frame: Before index admission to 24 months follow-up.
Diabetes control (HbA1c values)
Time frame: At baseline to 24 months follow-up
Plan to share: Undecided
Ran from Jan 2021 to primary completion in Nov 2023, 33 months.
Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's 33 months is below that.
Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Associacao para Investigacao e Desenvolvimento da Faculdade de Medicina - CETERA